[Source: InNexus] – InNexus Biotechnology Inc. , announced today that it has filed a Form 15-F with the United States Securities and Exchange Commission (“SEC”) to voluntarily de-register its common stock under the Securities Exchange Act of 1934 and continue its primary listing on the Toronto Stock Exchange (“TSX”) under the symbol of IXS.V. The Company considered many variables in its decision including the estimated savings of several hundreds of thousands of dollars each year, the limited investor pool on the over-the-counter-bulletin-board (“OTCBB”), and the fact that it has fewer than 300 shareholders. The Company intends to focus its efforts and dollars on its investor base, operations and TSX listing. The Company’s reporting obligations under the Securities Exchange Act, including InNexus’ obligation to file annual reports on Form 20-F and to submit reports on Form 6-K with the SEC, will no longer continue upon filing the Form 15-F.
For more information: INNEXUS Promotes Canadian TSX Venture Exchange Listing With Investors